NEW YORK (GenomeWeb News) – Gene Bridges said today that the Chugai Pharmaceutical has expanded a license for the company's recombination technology.

The Japanese pharmaceutical firm agreed to expand a commercial license for the Red/ET technology that the companies originally struck in 2005.

Patented in Japan as a "Novel DNA Cloning Method," the Red/ET technology is used for generating targeting vectors or modifying E. coli chromosomes. The methodology allows cloning, subcloning, and DNA modification at any position, Gene Bridges said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.

A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.

Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.